Selective N‐Terminal BET Bromodomain Inhibitors by Targeting Non‐Conserved Residues and Structured Water Displacement**-Reference-Cited by-同舟云学术

Selective N‐Terminal BET Bromodomain Inhibitors by Targeting Non‐Conserved Residues and Structured Water Displacement**

Published:2020-11-18 Issue:3 Volume:60 Page:1220-1226
ISSN:1433-7851
Container-title:Angewandte Chemie International Edition
language:en
Short-container-title:Angew. Chem. Int. Ed.

Author:

Cui Huarui¹^ORCID,Divakaran Anand²^ORCID,Pandey Anil K.¹,Johnson Jorden A.¹,Zahid Huda¹,Hoell Zachariah J.¹,Ellingson Mikael O.¹,Shi Ke³,Aihara Hideki³,Harki Daniel A.²^ORCID,Pomerantz William C. K.¹²^ORCID

Affiliation:

1. Department of Chemistry University of Minnesota-Twin Cities 207 Pleasant St. SE Minneapolis MN 55455 USA

2. Department of Medicinal Chemistry University of Minnesota-Twin Cities 2231 6^th St. SE Minneapolis MN 55455 USA

3. Department of Biochemistry, Molecular Biology, and Biophysics University of Minnesota-Twin Cities 321 Church St. SE Minneapolis MN 55455 USA

Funder

National Institute of General Medical Sciences

American Heart Association

National Institutes of Health

Masonic Cancer Center, University of Minnesota

Publisher

Wiley

Subject

General Chemistry,Catalysis

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/anie.202008625

Reference33 articles.

1. Translating the Histone Code

2. Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family

3. Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

4. Targeting bromodomains: epigenetic readers of lysine acetylation

5. NF-κB Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A BRD4‐Targeting Photothermal Agent for Controlled Protein Degradation;Angewandte Chemie International Edition;2024-06-17

2. A BRD4‐Targeting Photothermal Agent for Controlled Protein Degradation;Angewandte Chemie;2024-06-17

3. Research strategies of small molecules as chemotherapeutics to overcome multiple myeloma resistance;European Journal of Medicinal Chemistry;2024-05

4. Successes and challenges in the development of BD1-selective BET inhibitors: a patent review;Expert Opinion on Therapeutic Patents;2024-03-11

5. Discovery of a brain-permeable bromodomain and extra terminal domain (BET) inhibitor with selectivity for BD1 for the treatment of multiple sclerosis;European Journal of Medicinal Chemistry;2024-02